Carlos Arteaga Archives
Sep. 25, 2014—There are now approximately 14.5 million cancer survivors in the United States, thanks in large part to advances in cancer research and the development of new anti-cancer therapies.
Jul. 31, 2014—Two Vanderbilt-Ingram Cancer Center investigators have received multi-year breast cancer research grants from the Susan G. Komen for the Cure Breast Cancer Foundation.
May. 29, 2014—Despite a challenging health care landscape, Vanderbilt University Medical Center continues to advance the highest-quality patient care, train the next generation of physician leaders and push forward the frontiers of biomedical science.
Apr. 17, 2014—Carlos L. Arteaga, M.D., professor of Medicine and Cancer Biology and Donna S. Hall Professor of Breast Cancer Research at Vanderbilt-Ingram Cancer Center (VICC), assumed the presidency of the American Association for Cancer Research (AACR) for 2014-2015 during the group’s annual meeting last week in San Diego.
Nov. 25, 2013—Eighteen academic and administrative leaders at Vanderbilt University have been elected fellows of the American Association for the Advancement of Science (AAAS) this year.
Oct. 31, 2013—Vanderbilt-Ingram Cancer Center leaders formally dedicated the space for the new Center for Cancer Targeted Therapies (CCTT), located in the Infusion Center on the second floor of The Vanderbilt Clinic, at a special ribbon-cutting held during last week’s fall meeting of the Cancer Center’s Board of Overseers.
May. 9, 2013—Carlos Arteaga, M.D., professor of Medicine and Cancer Biology, has been appointed to lead two newly created cancer research initiatives at the Vanderbilt-Ingram Cancer Center.
Apr. 4, 2013—Carlos Arteaga, M.D., professor of Medicine and Cancer Biology at Vanderbilt, has been elected president-elect of the American Association for Cancer Research for 2013-2014.
Mar. 21, 2013—Many patients with triple-negative breast cancer (TNBC) have recurrence of their disease after an initial response to chemotherapy because the cancer cells have become resistant to treatment. TNBC has a lower survival rate because of this pattern of resistance and there are no targeted agents to treat this form of breast cancer.
Dec. 7, 2012—Most triple-negative breast cancer patients who were treated with chemotherapy to shrink the tumor prior to surgery still had multiple genetic mutations in their tumor cells, according to a study by Vanderbilt-Ingram Cancer Center (VICC) investigators.